Mauleti Ifael Yerosias, Wibisana Krishna Adi, Syamsuridzal Djati Prasetio, Mulyati Sri, Lisdawati Vivi, Hendarwan Harimat, Saptarini Ika
Department of Internal Medicine, Fatmawati General Hospital, Jakarta, Indonesia.
Department of General Practitioners, Fatmawati General Hospital, Jakarta, Indonesia.
J Prev Med Public Health. 2025 Jul;58(4):360-369. doi: 10.3961/jpmph.24.622. Epub 2025 Feb 22.
Current recommendations for managing human immunodeficiency virus (HIV) propose that initiating antiretroviral therapy (ART) promptly after diagnosis, regardless of CD4 cell count, may decrease illness and mortality risk. This study aimed to investigate factors associated with reduced mortality, including the time to ART initiation after diagnosis with HIV.
We conducted a retrospective cohort study using the medical records of 326 people living with human immunodeficiency virus (PLHIV) aged 18 years or older who initiated ART at a tertiary hospital between January 2018 and December 2022. We employed Cox regression models to estimate survival and identify mortality predictors, considering variables with p-values less than 0.05 as statistically significant.
From 2018 to 2022, 19.9% of PLHIV initiated ART within 7 days of diagnosis, and 57 participants died. The final multivariable Cox proportional hazards model indicated that earlier ART initiation significantly reduced mortality risk compared with starting ART more than 60 days after diagnosis, with adjusted hazard ratios of 0.36 for initiation within 7 days and 0.42 for initiation between 8 days and 60 days. Additional characteristics associated with reduced mortality risk included a CD4 count above 200 cells/mm 3 before ART initiation, a lower World Health Organization clinical stage, and tuberculosis post-exposure prophylaxis.
Earlier ART initiation significantly lowered mortality rates. Furthermore, a pre-ART CD4 count above 200 cells/mm3, a lower clinical stage, and tuberculosis preventive therapy were associated with reduced mortality risk among PLHIV. Future studies should investigate additional predictors of mortality within a prospective cohort study framework.
目前关于人类免疫缺陷病毒(HIV)管理的建议提出,确诊后立即开始抗逆转录病毒治疗(ART),无论CD4细胞计数如何,都可能降低疾病和死亡风险。本研究旨在调查与降低死亡率相关的因素,包括HIV诊断后开始ART的时间。
我们进行了一项回顾性队列研究,使用了2018年1月至2022年12月期间在一家三级医院开始接受ART治疗的326名18岁及以上的人类免疫缺陷病毒感染者(PLHIV)的病历。我们采用Cox回归模型来估计生存率并确定死亡预测因素,将p值小于0.05的变量视为具有统计学意义。
2018年至2022年期间,19.9%的PLHIV在诊断后7天内开始接受ART治疗,57名参与者死亡。最终的多变量Cox比例风险模型表明,与诊断后60天以上开始ART相比,更早开始ART显著降低了死亡风险,诊断后7天内开始治疗的调整风险比为0.36,8天至60天内开始治疗的调整风险比为0.42。与降低死亡风险相关的其他特征包括ART开始前CD4计数高于200个细胞/mm³、较低的世界卫生组织临床分期以及结核暴露后预防。
更早开始ART显著降低了死亡率。此外,ART开始前CD4计数高于200个细胞/mm³、较低的临床分期以及结核预防治疗与PLHIV的死亡风险降低相关。未来的研究应在前瞻性队列研究框架内调查其他死亡预测因素。